Icosavax is a biopharmaceutical company that develops vaccines for infectious diseases, focusing on respiratory diseases. They use virus-like particle (VLP) technology. Their pipeline includes vaccines for RSV, hMPV, and SARS-CoV-2, with some candidates in clinical trials. The company was founded in 2017 and is based in Seattle, Washington.